Implicit Bioscience Limited

Implicit Bioscience Limited is an Australian private clinical-stage biotechnology company based in Woolloongabba, Queensland. The company describes itself as "Transforming Immunotherapy" and is focused on the development of novel immunomodulatory medicines that act on the innate immune system. Its lead asset is IC14, also known as atibuclimab, a novel monoclonal antibody designed to block CD14, which the company describes as a master regulator of the body's immune response. By targeting CD14, IC14 aims to dampen excessive inflammatory signalling implicated in a range of acute and chronic conditions. The company's pipeline and research are centred on what it calls cardioimmunology — the intersection of cardiovascular disease and immune-mediated inflammation. Implicit Bioscience has pursued clinical development of IC14 in indications including heart failure, and has reported regulatory progress with the U.S. Food and Drug Administration. In December 2024 the company announced that the FDA had approved its drug for a clinical study in heart failure, with a first patient reported to be responding well to treatment. In January 2026 the company announced that the FDA had granted Fast Track designation to IC14 (atibuclimab). Implicit Bioscience operates as a private company and states that it welcomes support from philanthropists, private investors and government sources. It presents itself as a partnership-oriented organisation, seeking collaborations with researchers, clinicians, investors and industry partners to advance its programmes. The company emphasises that it has united world leaders in medical research, clinical practice and commercialisation within its team. Because it is a privately held, development-stage company, detailed financial information, ownership structure and full executive roster are not publicly disclosed in the available sources. Its public profile rests primarily on its scientific platform around CD14 blockade and its clinical and regulatory milestones in cardioimmunology.

Implicit Bioscience Limited is an Australian biotechnology company located in Woolloongabba, Queensland. It operates as a private, clinical-stage enterprise dedicated to immunotherapy, with a particular emphasis on modulating the innate immune system. The company's public identity is built around its lead programme, IC14 (atibuclimab), a novel monoclonal antibody that targets CD14, a receptor the company characterises as a master regulator of the body's immune response. The company's scientific strategy centres on cardioimmunology — the study and treatment of inflammatory mechanisms in cardiovascular disease. This focus has driven its clinical development efforts, notably in heart failure. On 1 December 2024, Implicit Bioscience announced that the U.S. Food and Drug Administration had approved its drug for a clinical study in heart failure, and that the first patient was reported to be responding well to treatment. This represented a significant step in translating the company's CD14-blockade platform into a clinical cardiovascular application. On 24 October 2025, the company's foundational cardioimmunology research received national attention when The Australian reported on the publication of its work. This coverage highlighted the scientific rationale underpinning the company's approach to treating heart disease through immune modulation. On 27 January 2026, Implicit Bioscience announced that the FDA had granted Fast Track designation to IC14 (atibuclimab). Fast Track designation is intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need, signalling regulatory recognition of the programme's therapeutic potential. Throughout its development, Implicit Bioscience has positioned itself as a collaborative venture, stating that it has united world leaders in medical research, clinical practice and commercialisation. As a private company, it has indicated that it welcomes support from philanthropists, private investors and government sources, and it actively seeks partnerships to advance its pipeline. Detailed information about its founding, early history, financing rounds and corporate ownership is not available in the public sources consulted.

• FDA approves Implicit drug for clinical study in heart failure; first patient reported to be responding well.

• The Australian reports on the publication of the company's foundational cardioimmunology work.

• FDA grants Fast Track designation to IC14 (atibuclimab).

Clinical-stage immunotherapy company focused on CD14 blockade and cardioimmunology; private, partnership- and investment-oriented.

• IC14 (atibuclimab)

  A novel monoclonal antibody designed to block CD14, a master regulator of the body's immune response. Under development for inflammatory and cardioimmune conditions including heart failure.

1. 1Implicit Bioscience | Transforming Immunotherapyimplicitbioscience.com
2. 2Implicit Bioscience Limited (Australia) - Wikidatawikidata.org